NEW YORK (GenomeWeb News) – Fitch Ratings today affirmed its long-term rating on Agilent Technologies' debt at 'BBB+' and revised its outlook to stable from positive, following Agilent's announcement earlier in the day that it would split into two separate, publicly traded firms.

Agilent said that the life sciences and diagnostics business, which also includes its genomics and applied markets products, will retain the Agilent name. It has annual revenues of around $3.9 billion.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.